Structured evidence table for Sulforaphane Skin Aging Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Sulforaphane Skin Aging Randomized Trial | Photoaging may not only affect quality of life, but also create substantial financial burden for patients, making its prevention and the practice of evidence-based treatments essential. | 3 | Tsai Jerry (2026) | Photoaging: Update on Pathogenesis, Prevention, and Treatment |
| Sulforaphane Skin Aging Randomized Trial | UVB, which primarily affects the epidermis and superficial dermis, is classically associated with the development of skin cancer through creation of cyclobutene pyrimidine dimers, pyrimidine-pyrimidone (6-4) photoproducts, and reactive oxygen species (ROS), as well as suppression of immune surveillance against tumors. | 3 | Tsai Jerry (2026) | Photoaging: Update on Pathogenesis, Prevention, and Treatment |
| Sulforaphane Skin Aging Randomized Trial | ECM degradation from chronic sun exposure also results in increased skin fragility and susceptibility of cutaneous vasculature to minor trauma, clinically manifesting as purpuric lesions known as solar purpura. | 3 | Tsai Jerry (2026) | Photoaging: Update on Pathogenesis, Prevention, and Treatment |
| Sulforaphane Skin Aging Randomized Trial | 1 2 Skin aging occurs through the passage of time (intrinsic aging) accompanied by environmental damage (extrinsic aging). | 3 | Tsai Jerry (2026) | Photoaging: Update on Pathogenesis, Prevention, and Treatment |
| Sulforaphane Skin Aging Randomized Trial | Acne, as one of the most common skin conditions, is prevalent among 85–90% of adolescents and young adults, and sunburn is almost universally experienced, with acute and long-term consequences including an increased risk of cutaneous malignancy [,,,,,]. | 3 | Liu Hua (2026) | Sulforaphane in Cutaneous Disorders and Skin Injury: Mechanisms, Evidence, and Clinical Perspectives |
| Sulforaphane Skin Aging Randomized Trial | In acne, current evidence supports a more complex pathogenesis involving sebaceous gland biology, follicular hyperkeratinization, host–microbiome interactions, and dysbiosis, rather than simple bacterial overgrowth alone []. | 3 | Liu Hua (2026) | Sulforaphane in Cutaneous Disorders and Skin Injury: Mechanisms, Evidence, and Clinical Perspectives |
| Sulforaphane Skin Aging Randomized Trial | Thus, there is a need for more mechanism- and evidence-based, scientifically validated, and well-tolerated complementary or adjunctive medicine approaches for these conditions [,,,]. | 3 | Liu Hua (2026) | Sulforaphane in Cutaneous Disorders and Skin Injury: Mechanisms, Evidence, and Clinical Perspectives |
| Sulforaphane Skin Aging Randomized Trial | 1 2 3 4 5 6 7 8 9 10 Cutaneous disorders and skin injury are among the most common chronic conditions, imposing significant physical, psychological, and socioeconomic burdens, warranting a multidimensional management approach. | 3 | Liu Hua (2026) | Sulforaphane in Cutaneous Disorders and Skin Injury: Mechanisms, Evidence, and Clinical Perspectives |
Source documents